Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Bernie Sanders Urges Ozempic Maker Novo Nordisk To Be Fair Over ‘Outrageously Expensive' U.S. Drug Prices
08:02am, Monday, 13'th May 2024
Bernie Sanders has urged Denmark to rein in its most valuable company, Novo Nordisk, and force it to slash prices on popular weight loss and diabetes treatments Ozempic and Wegovy, taking his fight to
Novo Nordisk weight loss rollout to prompt ‘dramatic upgrades' - analysts
07:58am, Monday, 13'th May 2024
Novo Nordisk (NYSE:NVO) could be in line for ‘dramatic earnings upgrades' as pace builds on the rollout of its weight loss drugs, analysts say. Wegovy sales could hit 76 billion Danish Krone (US$11
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
01:25pm, Sunday, 12'th May 2024
Novo Nordisk and Exelixis are favorites of billionaire Jim Simons' hedge fund. Novo Nordisk has a deep lineup and pipeline and expertise in diabetes and obesity.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
03:50am, Saturday, 11'th May 2024
Novo Nordisk's Ozempic has changed the business entirely. Eli Lilly is a diversified giant with GLP-1 tailwinds.
3 Million Reasons Novo Nordisk Still Looks Like a Phenomenal Buy
09:45am, Thursday, 09'th May 2024
Wegovy is a weight-loss drug that's proving it can do more than help people lose weight. Regulators recently approved it as a treatment for reducing cardiovascular risk.
Metaphore Biotechnologies to partner with Novo Nordisk on obesity therapies
07:20am, Thursday, 09'th May 2024
Metaphore Biotechnologies said on Thursday it would collaborate with Novo Nordisk to develop up to two therapies for obesity management.
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
10:30am, Wednesday, 08'th May 2024
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Novo Nordisk eyeing upside on US weight loss drug rollout - analysts
06:01am, Wednesday, 08'th May 2024
Novo Nordisk (NYSE:NVO) could see consensus estimates boosted over the coming years as sales of its weight loss drugs pick up in the US, analysts say. Novo has 12 million patients on its GLP-1-based
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
03:15pm, Tuesday, 07'th May 2024
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart monitoring tech was approved for use in clinical studies.
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
02:04pm, Tuesday, 07'th May 2024
Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
11:33am, Tuesday, 07'th May 2024
Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
06:45am, Saturday, 04'th May 2024
The outlook for Pfizer's experimental obesity drug danuglipron is murky at best. Pfizer could pick up another obesity drug via an acquisition, but management says a near-term deal is unlikely.
Apple, Glencore, Sony, Novo Nordisk, Shell, Goldman Sach, GSK, Qualcomm, AMD, Starbucks, Amazon – Markets Defused
06:01am, Saturday, 04'th May 2024
Markets Defused aims to present an easy-to-understand and straightforward recap of the week's most engaging stock market news Apple impressed Wall Street, Cook promises AI growth Sony stepped in wi
3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030
02:39pm, Friday, 03'rd May 2024
There are no true “under-the-radar stocks” in the traditional sense regarding companies with a market capitalization large enough to be viable candidates for a $1 trillion valuation in just six
Novo Nordisk continues to impress, says buyer Citi
10:00am, Friday, 03'rd May 2024
Novo Nordisk (NYSE:NVO)'s latest results have impressed analysts at Citi, who see little to stop the pharma's value increasing even further as weight control drug Wegovy grows in the US. “While peri
